Clinical Trial

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-04-25; most recent amendment 2026-05-20.
Status change: Not Yet Recruiting → Recruiting 2024-08-01
Trial Details
NCT Number NCT06386146
Lead Sponsor Jacobio Pharmaceuticals Co., Ltd.
Conditions Solid Tumors
Enrollment 144 participants
Start Date 2024-07-24
Primary Completion 2027-01 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-22